Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma have?
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma has 537 citations in the OpenAlex counts ScholarIQ stores.
When was Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma published?
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma has 2023 year in the ScholarIQ index.
What is the open-access status of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma?
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma has green oa status in the ScholarIQ index.
What is the DOI of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma?
The DOI for Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma is on the source record.
What is the PMID of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma?
The PMID for Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma is on the source record.
What is the OpenAlex record for Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma?
The OpenAlex for Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma is on the source record.